<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">clinvest</journal-id><journal-title-group><journal-title xml:lang="ru">Качественная клиническая практика</journal-title><trans-title-group xml:lang="en"><trans-title>Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2588-0519</issn><issn pub-type="epub">2618-8473</issn><publisher><publisher-name>ООО «Издательство ОКИ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/2588-0519-2024-1-63-71</article-id><article-id custom-type="edn" pub-id-type="custom">FAWAWZ</article-id><article-id custom-type="elpub" pub-id-type="custom">clinvest-707</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL TRIALS</subject></subj-group></article-categories><title-group><article-title>Идеальная скорость набора пациентов в клинических исследованиях II–III фаз</article-title><trans-title-group xml:lang="en"><trans-title>Ideal recruitment rate in clinical trials in phases II–III</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9843-6096</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Милованов</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Milovanov</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Милованов Святослав Сергеевич — к. м. н., независимый исследователь, аудитор GхP, специалист по клиническим исследованиям.</p><p>Москва</p></bio><bio xml:lang="en"><p>Svyatoslav S. Milovanov — Ph. D., independent researcher, Gxp Auditor, Clinical Research Specialist.</p><p>Moscow</p></bio><email xlink:type="simple">milovanovss@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ИП Милованов Святослав Сергеевич</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Individual entrepreneur Milovanov Svyatoslav Sergeevich</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>19</day><month>04</month><year>2024</year></pub-date><volume>0</volume><issue>1</issue><fpage>63</fpage><lpage>71</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Милованов С.С., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Милованов С.С.</copyright-holder><copyright-holder xml:lang="en">Milovanov S.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.clinvest.ru/jour/article/view/707">https://www.clinvest.ru/jour/article/view/707</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Скорость набора пациентов в клиническое исследование позволяет оценить работу клинического центра, произвести расчёт времени на достижение целевого набора. Авторы оценивают скорость набора на основании сопоставления с целевой величиной набора, и, по данным литературы, на скорость набора влияют множество факторов, которые в основном влияют отрицательно, уменьшая её. Оценки на оптимальность набора или нормальность набора пациентов по данным литературы всегда делались в расчёте на определённый протокол и нозологию, так как данный параметр невозможно сконструировать экспериментально в идеальных условиях при отсутствии влияния того или иного фактора. И, с другой стороны, большинство клинических исследований завершаются неудачей набора пациентов и, соответственно, скорость набора в таких исследованиях находилась под сильным влиянием тех или иных факторов.</p></sec><sec><title>Цель исследования</title><p>Цель исследования. Оценить количественно степень влияния фактора нозологии протокола на скорость набора пациентов в клиническом исследовании.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведён ретроспективный анализ 4-х международных мультицентровых клинических исследованиях II–III фаз по набору пациентов в зависимости от влияния фактора нозологии протокола. Использованы методы описательной статистики с типированием, методика расчёта отношения шансов.</p></sec><sec><title>Результаты</title><p>Результаты. Получена количественная оценка влияния фактора нозологии протокола на скорость набора пациентов, действие которого разнонаправленно — от не имеющего статически значимого влияния на скорость набора пациентов, до значительного влияния.</p></sec><sec><title>Выводы</title><p>Выводы. Впервые предложена количественная оценка факторов, влияющих на набор пациентов. Впервые найдена идеальная скорость набора пациентов.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Actuality</title><p>Actuality. The speed of patient recruitment into a clinical trial allows us to evaluate the work of the clinical center and calculate the time required to achieve targeted recruitment. The authors estimate the recruitment rate on the basis of comparison with the target recruitment value, and according to the literature, the recruitment rate is influenced by many factors, which mainly have a negative effect, reducing it. Assessments of the optimality of recruitment or the normality of recruitment of patients according to the literature were always made based on a specific protocol and nosology because this parameter cannot be constructed experimentally under ideal conditions in the absence of the influence of one or another factor. On the other hand, most clinical trials fail to recruit patients, and accordingly, the recruitment rate in such studies was strongly influenced by certain factors. For the first time, we assessed the patient recruitment rate in successful studies when calculating the degree of influence of the nosology and found the ideal recruitment rate, i. e., the recruitment rate with zero influence of the factor.</p></sec><sec><title>Objective</title><p>Objective. To quantify the degree of influence of the nosology factor of the protocol on the recruitment rate of patients in a clinical trial.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. A retrospective analysis of 4 international multicenter clinical trials of II–III phases was conducted on the recruitment of patients depending on the influence of the nosology factor of the protocol. Descriptive statistics using the typing and odds ratio technique.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. A quantitative assessment of the influence of the nosology factor of the protocol on the rate of patient recruitment was obtained. Found the ideal typing speed.</p></sec><sec><title>Conclusions</title><p>Conclusions. For the first time, a quantitative assessment of factors influencing patient recruitment has been proposed. For the first time, the ideal recruitment rate has been determined.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>клинические исследования</kwd><kwd>скорость набора пациентов</kwd><kwd>факторы набора пациентов</kwd><kwd>идеальная скорость набора пациентов</kwd></kwd-group><kwd-group xml:lang="en"><kwd>clinical trials</kwd><kwd>recruitment rate</kwd><kwd>recruitment factors</kwd><kwd>ideal recruitment rate</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнялась без спонсорской поддержки</funding-statement><funding-statement xml:lang="en">The work was carried out without sponsorship</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">van den Bor RM, Grobbee DE, Oosterman BJ, Vaessen PWJ, Roes KCB. Predicting enrollment performance of investigational centers in phase III multi-center clinical trials. Contemp Clin Trials Commun. 2017 Jul 20;7:208-216. doi: 10.1016/j.conctc.2017.07.004.</mixed-citation><mixed-citation xml:lang="en">van den Bor RM, Grobbee DE, Oosterman BJ, Vaessen PWJ, Roes KCB. Predicting enrollment performance of investigational centers in phase III multi-center clinical trials. Contemp Clin Trials Commun. 2017 Jul 20;7:208-216. doi: 10.1016/j.conctc.2017.07.004.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Schoenberger JA. Recruitment in the Coronary Drug Project and the Aspirin Myocardial Infarction Study. Clinical Pharmacology and Therapeutics. 1979 May;25(5 Pt 2):681-684. DOI: 10.1002/cpt1979255part2681.</mixed-citation><mixed-citation xml:lang="en">Schoenberger JA. Recruitment in the Coronary Drug Project and the Aspirin Myocardial Infarction Study. Clinical Pharmacology and Therapeutics. 1979 May;25(5 Pt 2):681-684. DOI: 10.1002/cpt1979255part2681.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Yang E, O'Donovan C, Phillips J, Atkinson L, Ghosh K, Agrafiotis DK. Quantifying and visualizing site performance in clinical trials. Contemp Clin Trials Commun. 2018 Jan 31;9:108-114. doi: 10.1016/j.conctc.2018.01.005.</mixed-citation><mixed-citation xml:lang="en">Yang E, O'Donovan C, Phillips J, Atkinson L, Ghosh K, Agrafiotis DK. Quantifying and visualizing site performance in clinical trials. Contemp Clin Trials Commun. 2018 Jan 31;9:108-114. doi: 10.1016/j.conctc.2018.01.005.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Reuter S, Esche G. How effective are site questionnaires in predicting site performance? Journal of Clinical Research Best Practices. 2007;3(4).</mixed-citation><mixed-citation xml:lang="en">Reuter S, Esche G. How effective are site questionnaires in predicting site performance? Journal of Clinical Research Best Practices. 2007;3(4).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Getz K. Predicting successful site performance. Applied Clinical Trials. 11-01-2011. Volume 20. Issue 11. https://www.appliedclinicaltrialsonline.com/view/predicting-successful-site-performance. [дата доступа: 01 march 2024].</mixed-citation><mixed-citation xml:lang="en">Getz K. Predicting successful site performance. Applied Clinical Trials. 11-01-2011. Volume 20. Issue 11. https://www.appliedclinicaltrialsonline.com/view/predicting-successful-site-performance. [дата доступа: 01 march 2024].</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemp Clin Trials Commun. 2018 Aug 7;11:156-164. doi: 10.1016/j.conctc.2018.08.001.</mixed-citation><mixed-citation xml:lang="en">Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemp Clin Trials Commun. 2018 Aug 7;11:156-164. doi: 10.1016/j.conctc.2018.08.001.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Chin Feman SP, Nguyen LT, Quilty MT, Kerr CE, Nam BH, Conboy LA, Singer JP, Park M, Lembo AJ, Kaptchuk TJ, Davis RB. Effectiveness of recruitment in clinical trials: an analysis of methods used in a trial for irritable bowel syndrome patients. Contemp Clin Trials. 2008 Mar;29(2):24151. doi: 10.1016/j.cct.2007.08.004.</mixed-citation><mixed-citation xml:lang="en">Chin Feman SP, Nguyen LT, Quilty MT, Kerr CE, Nam BH, Conboy LA, Singer JP, Park M, Lembo AJ, Kaptchuk TJ, Davis RB. Effectiveness of recruitment in clinical trials: an analysis of methods used in a trial for irritable bowel syndrome patients. Contemp Clin Trials. 2008 Mar;29(2):24151. doi: 10.1016/j.cct.2007.08.004.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Cook MJ. A survey report of the characteristics of the standard man. Oak ridge national laboratory, unpublished data, 1948.</mixed-citation><mixed-citation xml:lang="en">Cook MJ. A survey report of the characteristics of the standard man. Oak ridge national laboratory, unpublished data, 1948.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Snyder WS, Cook MJ, Nasset ES, Karhausen LR, Parry Howells G, Tipton IH. Report of the task group on reference man. − Oxford, 1975. − 496 p. https://koha.mdc-berlin.de/contents/01-00419.pdf. [дата доступа: 01 march 2024].</mixed-citation><mixed-citation xml:lang="en">Snyder WS, Cook MJ, Nasset ES, Karhausen LR, Parry Howells G, Tipton IH. Report of the task group on reference man. − Oxford, 1975. − 496 p. https://koha.mdc-berlin.de/contents/01-00419.pdf. [дата доступа: 01 march 2024].</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, Elbourne DR, Francis D, Garcia J, Roberts I, Snowdon C. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials. 2006 Apr 7;7:9. doi: 10.1186/1745-6215-7-9.</mixed-citation><mixed-citation xml:lang="en">McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, Elbourne DR, Francis D, Garcia J, Roberts I, Snowdon C. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials. 2006 Apr 7;7:9. doi: 10.1186/1745-6215-7-9.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Durant RW, Davis RB, St George DM, Williams IC, Blumenthal C, Corbie-Smith GM. Participation in research studies: factors associated with failing to meet minority recruitment goals. Ann Epidemiol. 2007 Aug;17(8):634-42. doi: 10.1016/j.annepidem.2007.02.003.</mixed-citation><mixed-citation xml:lang="en">Durant RW, Davis RB, St George DM, Williams IC, Blumenthal C, Corbie-Smith GM. Participation in research studies: factors associated with failing to meet minority recruitment goals. Ann Epidemiol. 2007 Aug;17(8):634-42. doi: 10.1016/j.annepidem.2007.02.003.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Милованов С.С. Новые подходы к оценке и классификации параметров набора пациентов для проведения II-III фаз клинических исследований. Южно-Российский журнал терапевтической практики. 2023;4(3):76-86. https://doi.org/10.21886/2712-8156-2023-4-3-76-86.</mixed-citation><mixed-citation xml:lang="en">Milovanov S.S. New approaches to the assessment and classification of patient's selection parameters for phase II-III clinical trials. South Russian Journal of Therapeutic Practice. 2023;4(3):76-86. (In Russ.) https://doi.org/10.21886/2712-8156-2023-4-3-76-86.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Вопросы здравоохранения. Рак. [Электронный ресурс]. URL: https://www.who.int/ru/news-room/fact-sheets/detail/cancer [дата доступа: 20.11.2022]</mixed-citation><mixed-citation xml:lang="en">Вопросы здравоохранения. Рак. [Электронный ресурс]. URL: https://www.who.int/ru/news-room/fact-sheets/detail/cancer [дата доступа: 20.11.2022]</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Cancer today. [Электронный ресурс]. URL https://gco.iarc.fr/ [дата доступа: 20.11.2022]</mixed-citation><mixed-citation xml:lang="en">Cancer today. [Электронный ресурс]. URL https://gco.iarc.fr/ [дата доступа: 20.11.2022]</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации по диагностике и лечению идиопатической тромбоцитопенической пурпуры (первичной иммунной тромбоцитопении) у взрослых. Научное гематологическое общество. [Электронный ресурс] URL https://npngo.ru/uploads/media_document/93/3d47f09e-0500-4d79-8dc0-688e6bc48636.pdf [дата доступа: 09.03.2024]</mixed-citation><mixed-citation xml:lang="en">Clinical guidelines for the diagnosis and treatment of idiopathic thrombocytopenic purpura (primary immune thrombocytopenia) in adults. Scientific Hematological Society. (Electronic resource).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Wild CP, Weiderpass E, Stewart BW, editors (2020). World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer. URL: http://publications.iarc.fr/586. [дата доступа: 01 марта 2024].</mixed-citation><mixed-citation xml:lang="en">Wild CP, Weiderpass E, Stewart BW, editors (2020). World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer. URL: http://publications.iarc.fr/586. [дата доступа: 01 марта 2024].</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность) − М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, − 2021. − ил. − 252 с.</mixed-citation><mixed-citation xml:lang="en">Kaprin A.D., Starinsky V.V., Shakhzadova A.O. Malignant neoplasms in Russia in 2020 (morbidity and mortality) − M.: MNIOI im. P.A. Herzen − branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia, − 2021. − ill. − 252 s.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Мерабишвили В.М., Дятченко О.Т. Статистика рака легкого (заболеваемость, смертность, выживаемость). Практическая Онкология. 2000;(3):3-7. https://practical-oncology.ru/articles/547.pdf.</mixed-citation><mixed-citation xml:lang="en">Merabishvili V.M., Dyatchenko O.T. Lung cancer statistics (morbidity, mortality, survival). Practical Oncology. 2000;(3):3-7. (in Russ).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Федеральная служба государственной статистики. URL: https://rosstat.gov.ru/storage/mediabank/Demograficheskie_pokazateli.xlsx дата доступа: 09.03.2024</mixed-citation><mixed-citation xml:lang="en">https://rosstat.gov.ru/storage/mediabank/Demograficheskie_pokazateli.xlsx [дата доступа: 09.03.2024 [Federal State Statistics Service. (access date: 09.03.2024). (in Russ).].</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660.</mixed-citation><mixed-citation xml:lang="en">Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, González-López TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019 Nov 26;3(22):3780-3817. doi: 10.1182/bloodadvances.2019000812.</mixed-citation><mixed-citation xml:lang="en">Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, González-López TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019 Nov 26;3(22):3780-3817. doi: 10.1182/bloodadvances.2019000812.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. Washington (DC): National Academies Press (US); 2010. Available from: https://www.ncbi.nlm.nih.gov/books/NBK50892/ doi: 10.17226/12900.</mixed-citation><mixed-citation xml:lang="en">Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. Washington (DC): National Academies Press (US); 2010. Available from: https://www.ncbi.nlm.nih.gov/books/NBK50892/ doi: 10.17226/12900.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Probstfield JL, Wittes JT, Hunninghake DB. Recruitment in NHLBI population-based studies and randomized clinical trials: data analysis and survey results. Control Clin Trials. 1987 Dec;8(4 Suppl):141S-149S. doi: 10.1016/0197-2456(87)90017-1.</mixed-citation><mixed-citation xml:lang="en">Probstfield JL, Wittes JT, Hunninghake DB. Recruitment in NHLBI population-based studies and randomized clinical trials: data analysis and survey results. Control Clin Trials. 1987 Dec;8(4 Suppl):141S-149S. doi: 10.1016/0197-2456(87)90017-1.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Lièvre M, Ménard J, Bruckert E, Cogneau J, Delahaye F, Giral P, Leitersdorf E, Luc G, Masana L, Moulin P, Passa P, Pouchain D, Siest G. Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. BMJ. 2001 Mar 10;322(7286):603-5. doi: 10.1136/bmj.322.7286.603.</mixed-citation><mixed-citation xml:lang="en">Lièvre M, Ménard J, Bruckert E, Cogneau J, Delahaye F, Giral P, Leitersdorf E, Luc G, Masana L, Moulin P, Passa P, Pouchain D, Siest G. Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. BMJ. 2001 Mar 10;322(7286):603-5. doi: 10.1136/bmj.322.7286.603.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Quick AM, Khaw PT, Elkington AR. Problems encountered in recruiting patients to an ophthalmic drug trial. The British Journal of Ophthalmology. 1989 Jun;73(6):432-434. DOI: 10.1136/bjo.73.6.432.</mixed-citation><mixed-citation xml:lang="en">Quick AM, Khaw PT, Elkington AR. Problems encountered in recruiting patients to an ophthalmic drug trial. The British Journal of Ophthalmology. 1989 Jun;73(6):432-434. DOI: 10.1136/bjo.73.6.432.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Hawkins BS, Prior MJ, Fisher MR, Blackhurst DW. Relationship between rate of patient enrollment and quality of clinical center performance in two multicenter trials in ophthalmology. Control Clin Trials. 1990 Oct;11(5):374-94. doi: 10.1016/0197-2456(90)90177-4.</mixed-citation><mixed-citation xml:lang="en">Hawkins BS, Prior MJ, Fisher MR, Blackhurst DW. Relationship between rate of patient enrollment and quality of clinical center performance in two multicenter trials in ophthalmology. Control Clin Trials. 1990 Oct;11(5):374-94. doi: 10.1016/0197-2456(90)90177-4.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Myers BA, Pillay Y, Guyton Hornsby W Jr, Shubrook J, Saha C, Mather KJ, Fitzpatrick K, de Groot M. Recruitment effort and costs from a multi-center randomized controlled trial for treating depression in type 2 diabetes. Trials. 2019 Nov 6;20(1):621. doi: 10.1186/s13063-019-3712-x.</mixed-citation><mixed-citation xml:lang="en">Myers BA, Pillay Y, Guyton Hornsby W Jr, Shubrook J, Saha C, Mather KJ, Fitzpatrick K, de Groot M. Recruitment effort and costs from a multi-center randomized controlled trial for treating depression in type 2 diabetes. Trials. 2019 Nov 6;20(1):621. doi: 10.1186/s13063-019-3712-x.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Jenei K, Haslam A, Olivier T, Miljkovíc M, Prasad V. What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020). BMJ Open. 2022 Oct 7;12(10):e064458. doi: 10.1136/bmjopen-2022-064458.</mixed-citation><mixed-citation xml:lang="en">Jenei K, Haslam A, Olivier T, Miljkovíc M, Prasad V. What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020). BMJ Open. 2022 Oct 7;12(10):e064458. doi: 10.1136/bmjopen-2022-064458.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
